Topline data were announced from the phase 2/3 DIAN-TU study of solanezumab (Eli Lilly) and gantenerumab (Genentech) in patients at risk for or with dominantly inherited Alzheimer disease.
Survey data published in JAMA Neurology indicate that approximately half of US adults perceive themselves to be at least somewhat likely to develop dementia.
A physically and mentally active lifestyle may protect against frontotemporal dementia even in people at established genetic risk.
Hearing loss is associated with higher levels of anxiety, interpersonal sensitivity, and hostility, as well as higher rates of dementia, especially in older adults who are also visually impaired.
Although 11.0% of individuals taking antidepressants developed dementia, only 2.6% of the unexposed sample went on to be diagnosed with dementia.
The United States has a rapidly ageing population, and 14 million people are projected to live with dementia by 2050.
Overall, ECT was a safe treatment option for patients with dementia experiencing agitation or aggression, as well as for those with comorbid medical conditions.
After a diagnosis of MCI has been established, patients should be counseled on treatment options.
Stepwise screening starts with a single question on subjective memory loss.
The USPSTF draft recommendation statement says there is inadequate evidence for weighing the benefits and harms of cognitive screening in older adults.
